Tandem’s new 7-day infusion set, the SteadiSet, has officially been cleared by the FDA and is set to launch in 2026. It features a redesigned coiled steel cannula with four micro-ports, extending wear time significantly. In clinical trials, 94% of sets lasted the full week—more than doubling the average infusion site lifespan.

Even bigger news: this same 7-day technology is being built into a tubeless version of the Mobi pump. For the first time, users will be able to choose between tubed and tubeless options on the same device. The tubeless Mobi is also expected in 2026, rolling out first in the U.S. In our latest podcast episode, I walk through the entire fill process for this future upgrade.

I sat down with Ben Mar, Tandem’s Senior Director of Product Marketing, for an in-depth conversation on the SteadiSet and tubeless Mobi. He gave me a hands-on demo of the new set, explained the tubeless Mobi setup, and shared updates on timelines, the upcoming Android app, its tubeless-first pump called Sigi, and what’s next for the company’s algorithm.

Ben also gave us more insight on recent safety warnings regarding a speaker malfunction on the t:slim X2 and another CGM glitch when overlapping G7 sensors that could lead to unwanted insulin (a must-hear for Tandem users).

You can catch the full interview above—or watch the video below.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.